Department of Orthopaedics, Lanzhou University Second Hospital, Lanzhou, 730000, Gansu, China.
Orthopaedics Key Laboratory of Gansu Province, Lanzhou, 730000, Gansu, China.
Hum Cell. 2021 Sep;34(5):1301-1309. doi: 10.1007/s13577-021-00556-6. Epub 2021 May 27.
Long non-coding RNA (lncRNA) is a type of non-coding RNA with length of nucleotides > 200 bp. Increasing evidences show that lncRNA breast cancer antiestrogen resistance 4 (BCAR4) plays an important role in the occurrence and development of various human cancers. It is found that BCAR4 is highly expressed in diverse tumor tissues and cells, and the high expression of BCAR4 is usually associated with poor prognosis. BCAR4 is considered as an oncogene in human cancers. By competing endogenous RNA (ceRNA) mechanism and regulating different signaling pathways, BCAR4 participates in the proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition (EMT), metastasis and tumorigenesis of different cancers. In addition, overexpression of BCAR4 promotes drug resistance of tumor cells. Therefore, BCAR4 is a promising biomarker for cancer diagnosis and prognosis, and it is a potential target for cancer therapy. This paper reviews studies focusing on the relationship between BCAR4 and cancers in recent years and aims to summarize the effect and mechanism of BCAR4 in human cancers.
长链非编码 RNA（lncRNA）是一种长度为核苷酸 > 200bp 的非编码 RNA。越来越多的证据表明，lncRNA 乳腺癌抗雌激素耐药蛋白 4（BCAR4）在各种人类癌症的发生和发展中起着重要作用。研究发现，BCAR4 在多种肿瘤组织和细胞中高表达，BCAR4 的高表达通常与预后不良有关。BCAR4 被认为是人类癌症中的癌基因。通过竞争性内源性 RNA（ceRNA）机制和调节不同的信号通路，BCAR4 参与了不同癌症的增殖、凋亡、迁移、侵袭、上皮-间充质转化（EMT）、转移和肿瘤发生。此外，BCAR4 的过表达促进了肿瘤细胞的耐药性。因此，BCAR4 是癌症诊断和预后的有前途的生物标志物，也是癌症治疗的潜在靶点。本文综述了近年来聚焦于 BCAR4 与癌症关系的研究，旨在总结 BCAR4 在人类癌症中的作用和机制。
